

**Minutes of the December 11, 2009
Pharmacy & Therapeutics (P&T) Committee Meeting
SD Department of Social Services, Medical Services Division**

Members present

Dana Darger, R.Ph.; Bill Ladwig, R.Ph.; Dennis Hedge, PharmD.; Rick Holm, M.D.; Debra Farver, PharmD.; Willis Sutliff, M.D.; Galen Goeden, R.Ph., Timothy Soundy, M.D., James Engelbrecht, M.D.

Members absent

Verdayne Brandenburg, M.D.

DSS staff present

Mike Jockheck, RPh; Larry Iversen, Director of Medical Services

HID staff present

Candace Rieth, Pharm.D.

Administrative Business

The P&T meeting was called to order by D. Darger at approximately 1:00pm. The minutes of the September 11, 2009 meeting were presented. G. Goeden made a motion to approve. D. Farver seconded the motion. The motion was approved unanimously.

Prior Authorization Statistics

C. Rieth presented an overview of the prior authorization (PA) activity for September 2009. There were a total of 2,174 PAs processed in the month of September, with 99.72% of those requests responded to in less than 8 hours. There were 1,940 (89%) requests received electronically and 234 (11%) requests received by fax. In response to a request from the committee, C. Rieth presented the number of approvals and denials, by form type, for the faxed (manual) PA requests.

Analysis of the Top 15 Therapeutic Classes

C. Rieth reviewed the Top 15 Therapeutic Classes by total cost of claims from 07/01/2009 – 09/30/2009. The top five classes were antipsychotics, anticonvulsants, cerebral stimulants, amphetamines, and antidepressants. The top 15 therapeutic classes make up 41.47% of total claims.

Antipsychotic Review

C. Rieth reviewed antipsychotic utilization with the P&T committee. At the September meeting, W. Sutliff made a motion that the psych experts on the committee develop a proposal for a tiered system for the antipsychotics and the antidepressants and present it at the December meeting. The committee reviewed the proposal. If a prior authorization is implemented, the committee made the recommendation that all recipients currently stable on therapy be grandfathered. The committee also suggested that a list of psychiatrists as well as mid-levels, supervised by a psychiatrist, be maintained and exempt from the prior authorization process. W. Sutliff made a motion to implement a prior authorization on antipsychotics and that a form and criteria be developed for the committee to review at the next meeting. D. Hedge seconded the motion. Phyllis Arends, representing NAMI, spoke against implementation of a prior authorization on antipsychotics. The motion was approved unanimously.

Antidepressant Review

C. Rieth reviewed antidepressant utilization with the P&T committee. At the September meeting, W. Sutliff made a motion that the psych experts on the committee develop a proposal for a tiered system for the antipsychotics and the antidepressants and present it at the December meeting. The committee reviewed the

proposal. The committee suggested that a list of psychiatrists as well as mid-levels, supervised by a psychiatrist, be maintained and exempt from the prior authorization process. B. Ladwig made a motion to implement a prior authorization on antidepressants and to exclude bupropion + SSRI and mirtazapine + SSRI from duplicate therapy rejection. G. Goeden seconded the motion. Phyllis Arends, representing NAMI, spoke against implementation of a prior authorization on antidepressants. Donna Linke, CNP, spoke against prior authorization of antidepressants. Lois Mastin, representing Forest, spoke against prior authorization of antidepressants. The motion was approved unanimously. A prior authorization form and criteria will be developed for the committee to review at the next meeting.

PPI Review

C. Rieth reviewed PPI utilization with the P&T committee. G. Goeden made a motion to take generic Prevacid off of prior authorization. B. Ladwig seconded the motion. There was no public comment. Motion passed unanimously.

Nuvigil/Provigil Review

C. Rieth reviewed Nuvigil/Provigil information with the P&T committee. A motion was made at the September meeting to place Nuvigil and Provigil on prior authorization. There was no public comment. The motion was approved unanimously.

ADHD Review

Because of time constraints, this topic will be reviewed at the March, 2010 meeting.

Savella Review

C. Rieth reviewed Savella information with the P&T committee. The committee tabled the discussion on Savella.

Sancuso Review

C. Rieth reviewed Sancuso information with the P&T committee. D. Farver made a motion that Sancuso be placed on prior authorization. B. Ladwig seconded the motion. There was no public comment. Motion passed unanimously.

The next meeting date is March 12, 2010. The location should remain the same. A motion was made by T. Soundy at 3 pm to adjourn the SD Medicaid P&T meeting. G. Goeden seconded. Motion passed unanimously and the meeting was adjourned.